Inscripta IPO
Inscripta is a biotechnology company that develops digital genome engineering platforms for cell programming applications. The company's technology enables precise, automated DNA editing at scale, which is valuable for applications in biomanufacturing, agriculture, and therapeutics. Investors are interested in Inscripta's potential to commercialize next-generation genome editing tools in growing synthetic biology markets.
Key Facts
| Industry | Biotechnology Tools |
| Founded | 2015 |
| Headquarters | Boulder, CO |
| Employees | ~300 |
| Website | inscripta.com |
| Funding | Series C funding. Total raised: ~$200M |
About Inscripta
Inscripta has developed automated genome editing platforms that enable researchers to make precise DNA modifications at unprecedented scale and speed. Their flagship Onyx platform can perform thousands of genome edits simultaneously, dramatically accelerating the development of new therapeutics, agricultural products, and industrial biotechnology applications.
The company's technology addresses a major bottleneck in biotechnology research where traditional genome editing methods are time-consuming and labor-intensive. By automating and parallelizing the editing process, Inscripta enables pharmaceutical companies, research institutions, and biotech startups to test multiple genetic modifications rapidly, potentially shortening drug discovery timelines from years to months. This capability is particularly valuable for developing cell and gene therapies, where precise genetic modifications are critical for therapeutic efficacy.
IPO Status
Inscripta has not announced any plans for an initial public offering. The company has raised significant venture capital funding to develop its digital genome engineering platform, but has kept details about its IPO timeline private. As a private biotechnology company, Inscripta would likely need to demonstrate significant commercial traction and regulatory progress before considering going public. The company continues to focus on developing and commercializing its genome engineering technology across various applications.
Competitors
Frequently Asked Questions
Does Inscripta have a stock?
No, Inscripta has not had an IPO and remains a private company. The biotechnology company has not announced any plans to go public at this time.
When is the Inscripta IPO date?
Inscripta has not announced an IPO date or timeline. No confirmed details are available about when the company might consider going public.
How can I buy Inscripta stock?
You cannot buy Inscripta stock as it is currently a private company. The stock would only become available for purchase by retail investors after a potential future IPO.
Stay Updated on the Inscripta IPO
Get real-time alerts when Inscripta files for an IPO, prices shares, or begins trading.
Get IPO Alerts